$AILE
iLearningEngines Inc

2022 Q3 Form 10-Q Financial Statement

#000114036122041473 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $355.5K $1.616M
YoY Change -78.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $355.5K $1.616M
YoY Change -78.0%
Operating Profit -$355.5K -$1.616M
YoY Change -78.0%
Interest Expense $1.230M $7.250K
YoY Change 16863.59%
% of Operating Profit
Other Income/Expense, Net $1.470M $6.561M
YoY Change -77.6%
Pretax Income $1.114M $4.953M
YoY Change -77.5%
Income Tax $244.0K $0.00
% Of Pretax Income 21.9% 0.0%
Net Earnings $870.3K $4.953M
YoY Change -82.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $24.22K $137.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $351.4K $379.3K
YoY Change -7.37%
Cash & Equivalents $351.4K $379.3K
Short-Term Investments
Other Short-Term Assets $205.8K $701.3K
YoY Change -70.66%
Inventory
Prepaid Expenses $205.7K
Receivables
Other Receivables
Total Short-Term Assets $557.1K $1.081M
YoY Change -48.44%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $288.8M $287.5M
YoY Change 0.44%
Other Assets $0.00
YoY Change
Total Long-Term Assets $288.8M $287.5M
YoY Change 0.44%
TOTAL ASSETS
Total Short-Term Assets $557.1K $1.081M
Total Long-Term Assets $288.8M $287.5M
Total Assets $289.3M $288.6M
YoY Change 0.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.054M $1.386M
YoY Change -23.97%
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.500M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.761M $1.386M
YoY Change 99.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.97M $22.96M
YoY Change -52.21%
Total Long-Term Liabilities $10.97M $22.96M
YoY Change -52.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.761M $1.386M
Total Long-Term Liabilities $10.97M $22.96M
Total Liabilities $13.73M $24.34M
YoY Change -43.59%
SHAREHOLDERS EQUITY
Retained Earnings -$12.62M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.62M $264.3M
YoY Change
Total Liabilities & Shareholders Equity $289.3M $288.6M
YoY Change 0.26%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $870.3K $4.953M
YoY Change -82.43%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$287.9K -$194.4K
YoY Change 48.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $216.0K $0.00
YoY Change
Cash From Investing Activities $216.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -287.9K -194.4K
Cash From Investing Activities 216.0K 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -71.93K -194.4K
YoY Change -63.0%
FREE CASH FLOW
Cash From Operating Activities -$287.9K -$194.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Marina Del Rey
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3961600
dei Entity Address Address Line1
EntityAddressAddressLine1
4553 Glencoe Ave, Suite 200
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-835972
dei Entity Registrant Name
EntityRegistrantName
ARROWROOT ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90292
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
566-5966
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
355529
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1615840
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1126963
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3013121
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1615840
us-gaap Operating Income Loss
OperatingIncomeLoss
-1126963
us-gaap Operating Income Loss
OperatingIncomeLoss
-3013121
CY2022Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
240000
CY2021Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
6561250
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
11081250
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
7775000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1592222
us-gaap Investment Income Interest
InvestmentIncomeInterest
16386
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12673472
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7791386
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1114333
arrw Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11546509
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4778265
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
244044
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
265764
us-gaap Net Income Loss
NetIncomeLoss
11280745
us-gaap Net Income Loss
NetIncomeLoss
4778265
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23180803
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-17259036
CY2022Q2 arrw Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
63459
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
4488689
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-12833806
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28276
CY2021Q1 arrw Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
28713942
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1630620
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-26395046
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1805013
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-28200059
arrw Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P24M
CY2022Q3 us-gaap Cash
Cash
351365
CY2022Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
288776642
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; font-variant: normal; text-transform: none;">Use of Estimates</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting periods.<br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these unaudited condensed financial statements is the</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly, the actual results could differ significantly from those estimates. </span></div>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
arrw Period To Exercise Warrants After Closing Of Initial Public Offering
PeriodToExerciseWarrantsAfterClosingOfInitialPublicOffering
P12M
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
arrw Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
760022
arrw Period To File Registration Statement After Initial Business Combination
PeriodToFileRegistrationStatementAfterInitialBusinessCombination
P15D
arrw Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
P60D
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.219
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.023
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q1 arrw Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
22625000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Concentration of Credit Risk</span></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</div>
CY2021Q1 arrw Number Of Director Nominees
NumberOfDirectorNominees
3
CY2021Q1 arrw Deferred Underwriter Fee Per Unit
DeferredUnderwriterFeePerUnit
0.35
CY2021Q1 arrw Deferred Underwriting Commissions
DeferredUnderwritingCommissions
10062500
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
arrw Stock Conversion Ratio
StockConversionRatio
1
CY2022Q3 arrw Stock Conversion As Converted Percentage
StockConversionAsConvertedPercentage
0.20
arrw Stock Conversion Ratio
StockConversionRatio
1
arrw Period To Exercise Warrants After Business Combination
PeriodToExerciseWarrantsAfterBusinessCombination
P30D
CY2022Q3 arrw Class Of Warrant Or Right Redemption Price
ClassOfWarrantOrRightRedemptionPrice
0.01
arrw Notice Period To Redeem Warrants
NoticePeriodToRedeemWarrants
P30D
arrw Threshold Trading Days
ThresholdTradingDays
P20D
arrw Threshold Consecutive Trading Days
ThresholdConsecutiveTradingDays
P30D
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
339214
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-355529
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7248
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1469862
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6568498
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
870289
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
4952658
CY2021Q1 arrw Underwriting Fees
UnderwritingFees
5750000
CY2021Q1 arrw Deferred Underwriting Commissions
DeferredUnderwritingCommissions
10062500
CY2021Q1 arrw Other Offering Costs
OtherOfferingCosts
580214
CY2021Q1 arrw Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10
CY2022Q3 arrw Net Tangible Asset Threshold For Redeeming Public Shares
NetTangibleAssetThresholdForRedeemingPublicShares
5000001
arrw Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
0
arrw Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
760022
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
281750000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8250000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
149992
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
149992
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
750000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
arrw Deferred Underwriting Fee Charged
DeferredUnderwritingFeeCharged
0
arrw Deferred Underwriting Fee Charged
DeferredUnderwritingFeeCharged
10062500
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
287500000
arrw Percentage Of Public Shares That Can Be Redeemed Without Prior Consent
PercentageOfPublicSharesThatCanBeRedeemedWithoutPriorConsent
0.15
CY2021Q1 arrw Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10
CY2021Q1 arrw Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10
CY2022Q3 arrw Working Capital Deficit
WorkingCapitalDeficit
-2134200
CY2022Q3 arrw Investment Income Interest Cumulative Amount
InvestmentIncomeInterestCumulativeAmount
1276642
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
339214
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001835972
arrw Period To Redeem Public Shares If Business Combination Is Not Completed Within Initial Combination Period
PeriodToRedeemPublicSharesIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
P10D
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1229862
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4952658
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
5921767
CY2022Q3 arrw Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
654605
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
870289
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-12618122
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
660000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
4952658
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-23247401
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
572862
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
16392714
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
16392714
CY2022Q3 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
339214

Files In Submission

Name View Source Status
0001140361-22-041473-index-headers.html Edgar Link pending
0001140361-22-041473-index.html Edgar Link pending
0001140361-22-041473.txt Edgar Link pending
0001140361-22-041473-xbrl.zip Edgar Link pending
arrw-20220930.xsd Edgar Link pending
brhc10043729_10q.htm Edgar Link pending
brhc10043729_ex31-1.htm Edgar Link pending
brhc10043729_ex31-2.htm Edgar Link pending
brhc10043729_ex32-1.htm Edgar Link pending
brhc10043729_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
arrw-20220930_cal.xml Edgar Link unprocessable
arrw-20220930_def.xml Edgar Link unprocessable
arrw-20220930_pre.xml Edgar Link unprocessable
arrw-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc10043729_10q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending